Asahi Kasei Therapeutics Corp. has identified new tumor necrosis factor receptor superfamily member 1A (TNFRSF1A; TNFR1; p55; CD120a) antagonists potentially useful for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, hidradenitis suppurativa, ulcerative colitis and Crohn's disease.